Background The discovery of somatostatin (SST) and the synthesis of a variety of analogues
constituted a major therapeutic advance in the treatment of gastroenteropancreatic …

Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which
may develop from different endocrine glands (such as the pituitary, the parathyroid or the …

Gastroenteropancreatic neuroendocrine tumours (GEP NETs) are rare tumours that present
many clinical features. They secrete peptides and neuroamines that cause distinct clinical …

Context: Dopamine receptor (DR) and somatostatin receptor subtype expression in pituitary
adenomas may predict the response to postsurgical therapies. Objectives: Our objectives …

Somatostatin (SST) is a small peptide that exerts inhibitory effects on a wide range of
neuroendocrine cells. Due to the fact that somatostatin regulates cell growth and hormone …

Introduction 3. Molecular and biochemical characterization of SSTRs 4. Physiological roles
of SSTRs 5. SSTRs and tumor cell proliferation 5.1 Direct antiproliferative effects 5.1. 1 …

Somatostatin (SS) and dopamine (DA) receptors have been highlighted as two critical
regulators in the negative control of hormonal secretion in a wide group of human endocrine …

The most recent World Health Organization classification of renal neoplasms encompassed
nearly 50 distinctive renal neoplasms. Different histological subtypes have different clinical …

There are two main subtypes of GH-producing pituitary adenoma: densely granulated (DG-
type) and sparsely granulated (SG-type). Despite the difference in drug responsiveness …

Introduction: Somatostatin and dopamine receptors are both G-protein-coupled receptors.
Somatostatin receptor (SSTR) expression in neuroendocrine tumours has been well …